A Study to Evaluate Rectal Cancer with Diffusion-Weighted and Dynamic Contrast Enhanced Perfusion-Weighted Magnetic Resonance Imaging


About this study

The purpose of this study is to analyze the apparent diffusion coefficient (ADC) from Diffusion-Weighted (DWI) in patients before, during the second week of and after preoperative chemoradiation therapy for rectal cancer.



Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult patients, ≥ 18 years of age.
  • Patients receiving definitive radiotherapy at Mayo Clinic Florida for locally advanced rectal cancer (T2-4NxM0; TxN+M0).

Exclusion Criteria: 

  • Adult patients not willing/able to provide informed consent.
  • Patients < 18 years of age.
  • Patients with HIV infection or Hepatitis infection.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Jeremy Jones, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions